|
1
|
Eccles SA, Aboagye EO, Ali S, Anderson AS,
Armes J, Berditchevski F, Blaydes JP, Brennan K, Brown NJ, Bryant
HE, et al: Critical research gaps and translational priorities for
the successful prevention and treatment of breast cancer. Breast
Cancer Res. 15:R922013. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Arnold M, Karim-Kos HE, Coebergh JW,
Byrnes G, Antilla A, Ferlay J, Renehan AG, Forman D and
Soerjomataram I: Recent trends in incidence of five common cancers
in 26 European countries since 1988: Analysis of the European
Cancer Observatory. Eur J Cancer. 51:1164–1187. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rahib L, Smith BD, Aizenberg R, Rosenzweig
AB, Fleshman JM and Matrisian LM: Projecting cancer incidence and
deaths to 2030: The unexpected burden of thyroid, liver, and
pancreas cancers in the United States. Cancer Res. 74:2913–2921.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stewart BW and Kleihues Paul P: World
Cancer Report. Lyon, France: International Agency Research on
Cancer; 2003
|
|
5
|
Shao S and Zhao X, Zhang X, Luo M, Zuo X,
Huang S, Wang Y, Gu S and Zhao X: Notch1 signaling regulates the
epithelial-mesenchymal transition and invasion of breast cancer in
a Slug-dependent manner. Mol Cancer. 14:282015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Barrio-Real L, Benedetti LG, Engel N, Tu
Y, Cho S, Sukumar S and Kazanietz MG: Subtype-specific
overexpression of the Rac-GEF P-REX1 in breast cancer is associated
with promoter hypomethylation. Breast Cancer Res. 16:4412014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gao J, Cai Q, Lu J, Jha HC and Robertson
ES: Upregulation of cellular Bcl-2 by the KSHV encoded rta promotes
virion production. PLoS One. 6:e238922011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xie L, Gazin C, Park SM, Zhu LJ, Debily
MA, Kittler EL, Zapp ML, Lapointe D, Gobeil S, Virbasius CM and
Green MR: A synthetic interaction screen identifies factors
selectively required for proliferation and TERT transcription in
p53-deficient human cancer cells. PLoS Genet. 8:e10031512012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Harper SJ and Bates DO: VEGF-A splicing:
The key to anti-angiogenic therapeutics? Nat Rev Cancer. 8:880–887.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rizzolio S and Tamagnone L: Semaphorin
signals on the road to cancer invasion and metastasis. Cell Adh
Migr. 1:62–68. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Miyato H, Tsuno NH and Kitayama J:
Semaphorin 3C is involved in the progression of gastric cancer.
Cancer Sci. 103:1961–1966. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Martin-Satué M and Blanco J:
Identification of semaphorin E gene expression in metastatic human
lung adenocarcinoma cells by mRNA differential display. J Surg
Oncol. 72:18–23. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rieger J, Wick W and Weller M: Human
malignant glioma cells express semaphorins and their receptors,
neuropilins and plexins. Glia. 42:379–389. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Neufeld G, Mumblat Y, Smolkin T, Toledano
S, Nir-Zvi I, Ziv K and Kessler O: The semaphorins and their
receptors as modulators of tumor progression. Drug Resist Updat.
29:1–12. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Feiner L, Webber AL, Brown CB, Lu MM, Jia
L, Feinstein P, Mombaerts P, Epstein JA and Raper JA: Targeted
disruption of semaphorin 3C leads to persistent truncus arteriosus
and aortic arch interruption. Development. 128:3061–3070.
2001.PubMed/NCBI
|
|
17
|
Brown CB, Feiner L, Lu MM, Li J, Ma X,
Webber AL, Jia L, Raper JA and Epstein JA: PlexinA2 and semaphorin
signaling during cardiac neural crest development. Development.
128:3071–3080. 2001.PubMed/NCBI
|
|
18
|
Herman JG and Meadows GG: Increased class
3 semaphorin expression modulates the invasive and adhesive
properties of prostate cancer cells. Int J Oncol. 30:1231–1238.
2007.PubMed/NCBI
|
|
19
|
Liao YL, Sun YM, Chau GY, Chau YP, Lai TC,
Wang JL, Horng JT, Hsiao M and Tsou AP: Identification of SOX4
target genes using phylogenetic footprinting-based prediction from
expression microarrays suggests that overexpression of SOX4
potentiates metastasis in hepatocellular carcinoma. Oncogene.
27:5578–5589. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Esselens C, Malapeira J, Colomé N, Casal
C, Rodríguez-Manzaneque JC, Canals F and Arribas J: The cleavage of
semaphorin 3C induced by ADAMTS1 promotes cell migration. J Biol
Chem. 285:2463–2473. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mishra R, Kumar D, Tomar D, Chakraborty G,
Kumar S and Kundu GC: The potential of class 3 semaphorins as both
targets and therapeutics in cancer. Expert Opin Ther Targets.
19:427–442. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hong CA and Nam YS: Functional
nanostructures for effective delivery of small interfering RNA
therapeutics. Theranostics. 4:1211–1232. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Burnett JC, Rossi JJ and Tiemann K:
Current progress of siRNA/shRNA therapeutics in clinical trials.
Biotechnol J. 6:1130–1146. 2011. View Article : Google Scholar : PubMed/NCBI
|
